Dosing characteristics of oral treprostinil in real-world clinical practice

von Balasubramanian, Vijay P., Messick, Chad R., Broderick, Meredith, Nelsen, Andrew C.
Veröffentlicht in Pulm Circ (2018)

Treatment satisfaction is associated with improved quality of life in patients treated with inhaled treprostinil for pulmonary arterial hypertension

von Chen, Hubert, Rosenzweig, Erika B, Gotzkowsky, S Karl, Arneson, Carl, Nelsen, Andrew C, Bourge, Robert C
Veröffentlicht 2013

Implantable system for treprostinil: a real-world patient experience study

von Shapiro, Shelley, Bourge, Robert C., Pozella, Patti, Harris, David F., Borg, Erick H., Nelsen, Andrew C.
Veröffentlicht in Pulm Circ (2020)

Correction to: Medication Adherence and Healthcare Costs Among Patients with Pulmonary Arterial Hypertension Treated with Oral Prostacyclins: A Retrospective Cohort Study

von Dean, Bonnie B., Saundankar, Vishal, Stafkey-Mailey, Dana, Anguiano, Rebekah H., Nelsen, Andrew C., Gordon, Kathryn, Classi, Peter
Veröffentlicht in Drugs Real World Outcomes (2020)

Medication Adherence and Healthcare Costs Among Patients with Pulmonary Arterial Hypertension Treated with Oral Prostacyclins: A Retrospective Cohort Study

von Dean, Bonnie B., Saundankar, Vishal, Stafkey-Mailey, Dana, Anguiano, Rebekah H., Nelsen, Andrew C., Gordon, Kathryn, Classi, Peter
Veröffentlicht in Drugs Real World Outcomes (2020)

Impact of inhaled treprostinil on risk stratification with noninvasive parameters: a post hoc analysis of the TRIUMPH and BEAT studies

von Tonelli, Adriano R., Sahay, Sandeep, Gordon, Kathryn W., Edwards, Lisa D., Allmon, Andrew G., Broderick, Meredith, Nelsen, Andrew C.
Veröffentlicht in Pulm Circ (2020)

Identifying Patients with Pulmonary Arterial Hypertension Using Administrative Claims Algorithms

von Mathai, Stephen C., Hemnes, Anna Ryan, Manaker, Scott, Anguiano, Rebekah H., Dean, Bonnie B., Saundankar, Vishal, Classi, Peter, Nelsen, Andrew C., Gordon, Kathryn, Ventetuolo, Corey E.
Veröffentlicht in Ann Am Thorac Soc (2019)

Bronchodilation induced by PGE(2) is impaired in Group III pulmonary hypertension

von Ozen, Gulsev, Benyahia, Chabha, Mani, Salma, Boukais, Kamel, Silverstein, Adam M., Bayles, Richard, Nelsen, Andrew C., Castier, Yves, Danel, Claire, Mal, Hervé, Clapp, Lucie H., Longrois, Dan, Norel, Xavier
Veröffentlicht in Br J Pharmacol (2019)

The Influence of CYP3A5 Genotype on Dexamethasone Induction of CYP3A Activity in African Americans

von Roberts, Patrick J., Rollins, Kristan D., Kashuba, Angela D. M., Paine, Mary F., Nelsen, Andrew C., Williams, Eric E., Moran, Cassandra, Lamba, Jatinder K, Schuetz, Erin G., Hawke, Roy L.
Veröffentlicht 2008

Pulmonary hypertension due to interstitial lung disease or chronic obstructive pulmonary disease: a patient experience study of symptoms and their impact on quality of life

von DuBrock, Hilary M., Nathan, Steven D., Reeve, Bryce B., Kolaitis, Nicholas A., Mathai, Stephen C., Classi, Peter M., Nelsen, Andrew C., Olayinka-Amao, Bimpe, Norcross, Lindsey N., Martin, Susan A.
Veröffentlicht in Pulm Circ (2021)

Rapid Transition from Inhaled Iloprost to Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension

von Bourge, Robert C, Tapson, Victor F, Safdar, Zeenat, Benza, Raymond L, Channick, Richard N, Rosenzweig, Erika B, Shapiro, Shelley, White, Richard James, McSwain, Christopher Shane, Gotzkowsky, Stephen Karl, Nelsen, Andrew C, Rubin, Lewis J
Veröffentlicht 2013